EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia

Maria A. Dunaykina, L. N. Shelikhova, S. L. Blagov, M. A. Klimentova, M. E. Perminova, E. Yu. Osipova, R. V. Nikolaev, M. V. Efimenko, G. G. Solopova, D. N. Balashov, A. A. Maschan, M. A. Maschan

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 37-49

DOI: 10.24287/j.1139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Maria A. Dunaykina und 11 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using a TCRαβ/CD19 depletion platform is associated with a low incidence of graft-versus-host disease, however, delayed immune reconstitution increases the risk of opportunistic viral reactivation. Aim: to analyze the kinetics of pathogen-specific immune reconstitution and its impact on clinical outcomes of allo-HSCT. Materials and methods. We performed a retrospective analysis on a cohort of 265 children from the prospective database of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All patients underwent their first allo-HSCT from a haploidentical donor with TCRαβ/CD19 depletion between September 2016 and March 2022. Pathogen-specific T-cell responses were assessed by IFN-γ ELISPOT assays (cutoff ≥10 SFC/3 × 10⁵ MNC) on days +30, +60, +90, +180, and at 1 year after allo-HSCT.

Results

For cytomegalovirus (CMV), the proportion of ELISPOT-positive patients increased from 38.5 to 70% during the first year after allo-HSCT. For adenovirus, the proportion of ELISPOT-positive patients was 7% on day +30, 16% on day +90, and 38–49% from day +180 to 1 year. For Epstein–Barr virus, the proportion of ELISPOT-positive patients reached 22% at 1 year after allo-HSCT. On day +30, SFC counts for CMV showed the strongest correlation with CD3⁺CD8⁺ T cells; by 1 year, this association was no longer evident (R² = 0.005; p = 0.058). CMV ELISPOT positivity on day +30 correlated with CMV reactivation (57% vs 42%; p = 0.012), reflecting the effect of antigenic stimulation on T cell expansion. On day +60, ELISPOT positivity predicted a more favorable course of viremia, including a shorter duration of viremia (4 weeks vs 6 weeks; p = 0.023) and a lower peak viral load (9587 copies/mL vs 23 525 copies/mL; p = 0.029). The cumulative risk of transplant-related mortality was 3% (95% confidence interval 2–6); the trend toward lower transplant-related mortality in patients with ELISPOT positivity on day +30 did not reach statistical significance (1% vs 4%; p = 0.798).

Conclusion

Therefore, reconstitution of pathogen-specific immunity after allo-HSCT is antigen-dependent. The presence of virus-specific T cells is associated with more effective control of viremia.

Zitieren

APA

Dunaykina, M. A., Shelikhova, L. N., Blagov, S. L., Klimentova, M. A., Perminova, M. E., Osipova, E. Y., Nikolaev, R. V., Efimenko, M. V., Solopova, G. G., Balashov, D. N., Maschan, A. A., & Maschan, M. A. (2026). Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia. Pediatric Hematology/Oncology and Immunopathology, 25(2), 37-49. https://doi.org/10.24287/j.1139

Vancouver

Dunaykina MA, Shelikhova LN, Blagov SL, Klimentova MA, Perminova ME, Osipova EY, et al. Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):37-49. doi:10.24287/j.1139

BibTeX
@article{Dunaykina2026,
  author = {Dunaykina, Maria A. and Shelikhova, L. N. and Blagov, S. L. and Klimentova, M. A. and Perminova, M. E. and Osipova, E. Yu. and Nikolaev, R. V. and Efimenko, M. V. and Solopova, G. G. and Balashov, D. N. and Maschan, A. A. and Maschan, M. A.},
  title = {Pathogen-specific immune reconstitution after hematopoietic stem cell transplantation using an αβ T cell depletion platform in children with acute leukemia},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {37--49},
  doi = {10.24287/j.1139}
}
Kostenlos starten →